Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of bortezomib + bendamustine + dexamethasone in relapsed or refractory multiple myeloma
2008-006421-13Phase 2Completed
- Sponsor
- Wilhelminen Cancer Research Institute
- Start
- Nov 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib, bendamustine and dexamethasone in multiple myeloma (MM), sponsored by Wilhelminen Cancer Research Institute. Primary endpoint: Overall response rate (CR + PR). Started Nov 2008; status: completed.
02
Drugs
bortezomibbendamustinedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2008-006421-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006421-13.